Skip to main content

Table 7 Performance of cefiderocol AST methods in comparison with UMIC® reference method

From: TROJAN-MDR: in vitro activity of cefiderocol and comparators against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in Southern France, evaluation of available testing methods performances

AST method

Enterobacterales (n = 127)

P. aeruginosa (n = 53)

CA (%)

EA (%)

VME (%)

ME (%)

Difference of bias (%)

CA (%)

EA (%)

VME (%)

ME (%)

Difference of bias (%)

ComASP® BMD

85.8

65.4

65.2

2.9

− 49.6

86.8

58.5

87.5

0

− 60.2

BD BBL™ MH II agar DD

89 (73.2)

NA

21.1 (17.4)

8.6 (28.8)

NA

96 (94.3)

NA

33.3 (25)

0 (2.2)

NA

Bio-Rad MH agar DD

87 (74)

NA

37.5 (26.1)

8.3 (26)

NA

88.2 (88.7)

NA

100 (75)

0 (0)

NA

  1. EUCAST 2024 clinical breakpoints were used for the interpretation of the results. Values in brackets are the performance when the ATU is ignored
  2. CA Categorical Agreement, EA Essential Agreement, VME Very MajorEerrors, ME Major Errors, BMD Broth MicroDilution, DD Disk Diffusion, NA Non-Applicable